Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observational Study of GIOTRIF (Afatinib) for First Line Therapy in Patients With Advanced Non Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR)-Mutations

Trial Profile

An Observational Study of GIOTRIF (Afatinib) for First Line Therapy in Patients With Advanced Non Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR)-Mutations

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afatinib (Primary)
  • Indications Carcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms GIDEON
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 10 Sep 2019 Results of a pooled analysis of Asian phase IIIB trial and a German non-interventional study assessing the sensitivity of uncommon EGFR mutations to afatinib, presented at the 20th World Conference on Lung Cancer
    • 09 Jan 2019 Status changed from active, no longer recruiting to completed.
    • 05 Sep 2017 Planned primary completion date changed from 1 Nov 2018 to 31 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top